Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PVS1_StrongPM2PP3PP5_Very_Strong
The NM_001042432.2(CLN3):c.1195G>T(p.Glu399*) variant causes a stop gained, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
CLN3 (HGNC:2074): (CLN3 lysosomal/endosomal transmembrane protein, battenin) This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008]
Verdict is Pathogenic. Variant got 15 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 7 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 16-28477739-C-A is Pathogenic according to our data. Variant chr16-28477739-C-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 56250.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-28477739-C-A is described in Lovd as [Pathogenic].
Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM)
Significance: Likely pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only
- -
Mar 14, 2024
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Apr 17, 2017
Counsyl
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not provided Pathogenic:2
Sep 11, 2024
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing
Reported with second CLN3 variant, phase unknown, in a patient with juvenile neuronal ceroid lipofuscinosis (PMID: 21990111); Nonsense variant predicted to result in protein truncation, as the last 40 amino acid(s) are lost, and other loss-of-function variants have been reported downstream in HGMD; Published functional studies demonstrate that protein truncation affects localization of CLN3 to the lysosomes and retains the protein in the endoplasmic reticulum (PMID: 14699076); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25976102, 31568712, 36034292, 21990111, 14699076) -
Jul 01, 2019
CeGaT Center for Human Genetics Tuebingen
Significance: Pathogenic
Review Status: criteria provided, single submitter